Question: Cannabis cessation and neurocognitive recovery: Patterns, predictors, and clinical implications—a systematic review

A 19-year-old male presents for treatment of cannabis use disorder. He reports daily use since age 14. After 4 weeks of verified abstinence, he continues to show deficits in verbal working memory. Which of the following best explains this clinical picture based on the available evidence?

According to the neuroimaging evidence reviewed, approximately how long does it take for brain CB1 receptor density to return to normal levels following cannabis cessation in chronic daily users?

A clinician is counseling a 28-year-old adult-onset cannabis user who has been abstinent for 3 months. He reports persistent difficulties concentrating at work. Which of the following recommendations is most consistent with the evidence reviewed?

Which of the following cognitive domains showed the most rapid improvement following cannabis cessation, with significant gains evident within the first week of verified abstinence?

A clinical trial included in this review examined a pharmacological agent that showed dual benefits of reducing cannabis use AND improving executive function performance compared to placebo. Which agent was evaluated in that trial?

Based on the systematic review findings, which of the following patient profiles represents the highest risk for incomplete neurocognitive recovery following cannabis cessation?